Minervax develops of a novel vaccine candidate against Group B Streptococci (GBS). GBS is the leading cause of life-threatening bacterial infections in newborn babies affecting some 8,000 babies annually in Europe and the US. GBS infections may result in still-births, or pneumonia, septicaemia and meningitis in the newborn babies leading to either severe morbidity, mortality or life-long disabilites. The National Institute of Health of the US has identified prevention of GBS in newborns as a major vaccine objective, but so far no approved or universally useful vaccine exists. A general vaccine effective against relevant strains of GBS is poised to have great impact and could potentially be administered to pregnant women or adolescent women as part of a general vaccine program. Minervax’ GBS vaccine candidate is currently in clinical development.

Sten Verland, PhD MSc

General Partner

Mobile: +45 24 22 19 69